Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.
Latest from Mary Jo Laffler
Submit your drug development programs for recognition at the 2025 Citeline Awards. The deadline has been extended to 28 February.
Submit your drug development programs for recognition at the 2025 Citeline Awards. The deadline has been extended to 28 Feb.
BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.
The action, taken in consultation with the US FDA, follows the failure of the TROPiCS-04 study, which was the confirmatory trial for the urothelial cancer accelerated approval.
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.